Semaglutide is a GLP‑1 receptor agonist widely recognized for its dual role in type 2 diabetes management and weight loss therapy.
Benefits
- Proven Efficacy: FDA‑approved for diabetes and obesity, with strong clinical backing.
- Cardiovascular Outcomes: Reduces risk of major adverse cardiac events.
- Flexible Formulations: Available in both oral and injectable forms.
- Appetite Regulation: Enhances satiety, reducing caloric intake.
Applications
- Research into long‑term obesity management.
- Studies on cardiovascular protection in diabetic patients.
- Comparative trials with Tirzepatide for efficacy benchmarks.
Consumption & Measurements
- Administered via weekly injection or daily oral tablet.
- Measurements include fasting glucose, HbA1c, body weight, and waist circumference.
- Research protocols often assess satiety hormones and appetite regulation.
